Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495245 | 1.00 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16495246 | 1.00 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2474507 | 0.89 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16495068 | 0.89 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2474494 | 0.89 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2470816 | 0.86 | P2RY2 (0.44) | P2RY2P2RY14P2RY4P2RY6ENPP1 | |
| SCHEMBL2471085 | 0.83 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2470248 | 0.80 | RNASEL (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2470251 | 0.80 | RNASEL (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2470239 | 0.80 | RNASEL (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329318-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | WAVE LIFE SCIENCES LTD. (SG) | 2019-06-25 | — | — | US | disclosed |
| US-20180111958-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES JAPAN, INC. (JP) | 2018-04-26 | — | — | US | disclosed |
| US-9695211-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | WAVE LIFE SCIENCES JAPAN, INC. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160347780-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES LTD. (SG) | 2016-12-01 | — | — | US | disclosed |
| EP-2370451-B1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES JAPAN INC (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-9394333-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | WAVE LIFE SCIENCES JAPAN (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20110294124-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES LTD. (SG) | 2011-12-01 | — | — | US | disclosed |
| EP-2370451-A2 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | Chiralgen, Ltd. (JP) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010064146-A2 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | CHIRALGEN, LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111958-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | PNP, ADAR, NUDT1 | SLC28A1 277/4885SLC28A2 275/4885SLC29A1 85/4885 |
| US-10329318-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | PNP, ADAR, NUDT1 | SLC28A1 277/4885SLC28A2 275/4885SLC29A1 85/4885 |
| US-20110294124-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | PNP, ADAR, NUDT1 | SLC28A1 277/4885SLC28A2 275/4885SLC29A1 85/4885 |
| US-20160347780-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | ADAR, PNP, NUDT1 | SLC28A1 297/4885SLC28A2 307/4885SLC29A1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.